General MedicationsORALGeneric
TAPENTADOL
TAPENTADOL
Standard Dose
250MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary
Approval overview TAPENTADOL is listed in Drugs@FDA under application 206418 (ANDA).
Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient TAPENTADOL Form and strength TABLET, EXTENDED RELEASE;ORAL - 250MG Sponsor WEST-WARD PHARMS INT Submission history Latest submission status date: 2026-02-13 00:00:00.
Structured Monograph
Clinical summary
Approval overview TAPENTADOL is listed in Drugs@FDA under application 206418 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient TAPENTADOL Form and strength TABLET, EXTENDED RELEASE;ORAL - 250MG Sponsor WEST-WARD PHARMS INT Submission history Latest submission status date: 2026-02-13 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: None (Tentative Approval)
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.